U.S. pharma bounced back in Q2, and in this episode of "The Top Line," Fierce Pharma's Eric Sagonowsky and Kevin Dunleavy ...

CheqUp said it had experienced a spike in interest from consumers wanting to switch or begin taking the medication.

New recommendations suggest holding back on SGLT2 inhibitors and GLP-1s among those at a lower risk for cardiovascular or ...

If approved, AbbVie's Rinvoq could be set to dominate the alopecia market after exhibiting better efficacy than main ...

GLP-1 drugs were also associated with a slight increase in risk for kidney cancer. The increase was not statistically ...

Eli Lilly and Company faces a pivotal period with the upcoming retirement of Anne White, a key neuroscience leader set for ...

J&J said on Thursday it has reached a 10-year agreement with Tokyo-based contract drug developer Fujifilm Biotechnologies for ...

The U.S. and European Union announced they reached a trade agreement that would cap tariffs on branded pharmaceuticals at 15%.

This is all you need to know about the new weight loss jab 'Reta' that's said to be 3 times stronger than Ozempic.

Johnson & Johnson announces a $2 billion North Carolina manufacturing expansion as part of a broader U.S. onshore ...

This week on "The Readout LOUD," we discuss Viking Therapeutics' obesity flop and dish on the growing "pharm to table" movement.

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030.